Andean Precious Metals Q4 2022 Earnings Report C$1.29 +0.09 (+7.50%) As of 01/8/2025 Earnings HistoryForecast Andean Precious Metals EPS ResultsActual EPS-C$0.03Consensus EPS -C$0.03Beat/MissMet ExpectationsOne Year Ago EPSN/AAndean Precious Metals Revenue ResultsActual Revenue$34.85 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AAndean Precious Metals Announcement DetailsQuarterQ4 2022Date3/16/2023TimeN/AConference Call ResourcesAPM Earnings History Andean Precious Metals Earnings HeadlinesAndean Precious Metals Corp. (APM.TO)January 16 at 2:12 PM | finance.yahoo.comReturns On Capital Signal Tricky Times Ahead For Andean Precious Metals (CVE:APM)December 11, 2024 | finance.yahoo.comBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $125,000 by the end of his first month in office.January 18, 2025 | Weiss Ratings (Ad)Andean Precious Metals: Stocks Overvalued by Analyst Consensus on TSX-V (APM)October 26, 2024 | theglobeandmail.comA&W Revenue, Bombardier, Blackrock at 52-Week Highs on NewsOctober 15, 2024 | baystreet.caMonday’s Insider Report: Billionaire Eric Sprott is buying two penny stocks with massive returns in 2024October 7, 2024 | theglobeandmail.comSee More Andean Precious Metals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Andean Precious Metals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Andean Precious Metals and other key companies, straight to your email. Email Address About Andean Precious MetalsAptorum Group Limited, a pharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of diseases with a focus on infectious diseases and cancers. Its pipeline enables the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platform for treatments of metabolic diseases. The company also focuses on therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women's health, and other disease areas. In addition, it operates a medical clinic. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom.View Andean Precious Metals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Why Amazon’s Next Earnings Could Trigger a Stock BreakoutS&P 500 Earnings Set to Shine: January's Critical Market TestCiena Rebounds: AI and Strong Guidance Drive Post-Earnings SurgeHistory Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead? Upcoming Earnings Interactive Brokers Group (1/21/2025)Netflix (1/21/2025)Capital One Financial (1/21/2025)HDFC Bank (1/21/2025)3M (1/21/2025)Prologis (1/21/2025)Charles Schwab (1/21/2025)Abbott Laboratories (1/22/2025)Amphenol (1/22/2025)GE Vernova (1/22/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
